Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01059552 · ClinicalTrials.gov registry record · Phase 1
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01059552 is a Phase 1 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 18 participants.
The verdict
NCT01059552, a Phase 1 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.
Interventions
- DRUG vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-12-16 |
| Est. Completion | 2019-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01059552
The ClinicalTrials.gov registry entry for NCT01059552 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vorinostat is the first listed.
NCT01059552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01059552 about?
NCT01059552 is a clinical study titled "Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to determine the maximum tolerated dose of the combination of vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage IIIA/IIIB non-small cell lung cancer.
What is the current status of trial NCT01059552?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-12-16. Estimated completion is 2019-10-21.
What interventions are being tested in trial NCT01059552?
The interventions under investigation include: vorinostat (DRUG).
Who is sponsoring clinical trial NCT01059552?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.